Aneurysmal subarachnoid haemorrhage: thunderclap headache and early neurovascular care

Clinical scope and immediate priorities

Aneurysmal subarachnoid haemorrhage is a time-critical cause of sudden severe headache with risks of rebleeding, hydrocephalus, delayed cerebral ischaemia and systemic complications. A normal neurological examination does not exclude SAH, especially early after the bleed. Neurological assessment depends on chronology, focality, level of consciousness and careful exclusion of mimics. Time-sensitive disorders require parallel diagnostic and treatment pathways because waiting for every result can cause avoidable harm. Functional baseline, swallowing, cognition, mobility and medication effects also influence disposition and follow-up.

Recognition and differential diagnosis

The classic presentation is headache reaching maximal intensity within seconds to a minute, often described as the worst or most abrupt headache experienced. Neck stiffness, vomiting, collapse, photophobia or focal deficits may occur. Exertion, sexual activity or Valsalva can precede onset but are not required. Sentinel headaches can occur before major rupture. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Urgent non-contrast CT is the first test. When CT is negative but clinical suspicion remains, the need for lumbar puncture or CT angiography depends on timing, scanner quality and local pathway. Once SAH is confirmed, vascular imaging identifies an aneurysm and guides endovascular or surgical treatment. Grade clinical severity and monitor for hydrocephalus. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Control pain and blood pressure carefully, avoid hypotension and start nimodipine according to guideline protocols to reduce delayed ischaemic complications. Secure the ruptured aneurysm as early as feasible by endovascular coiling or surgical clipping based on anatomy and specialist assessment. Treat hydrocephalus and seizures when present rather than prophylactically in all patients. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

All confirmed aneurysmal SAH requires specialist neurovascular care. Deteriorating consciousness, new focal deficit or rising intracranial pressure requires urgent reassessment for rebleeding, hydrocephalus, delayed cerebral ischaemia or metabolic complications. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Survivors need rehabilitation and follow-up for cognitive, mood and fatigue symptoms, which may persist despite good motor recovery. Smoking and blood-pressure management are important risk-reduction measures.

Common pitfalls and safety checks

Do not dismiss a thunderclap headache because the patient looks well after analgesia. A negative early CT reduces risk but does not end evaluation when pre-test suspicion remains high under the local diagnostic pathway. Avoid unnecessary delays in securing the aneurysm. Long-term cognitive and fatigue effects can be substantial even when the neurological examination is normal. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Neurological safety depends heavily on transitions of care. Record the patient’s pre-event function, cognition, swallowing, driving or occupational implications and whether family or carers have observed features not seen in clinic. Time-critical imaging and treatment pathways vary in organisation, but delays should be measured and reviewed. Before discharge, make explicit which recurrent symptoms are emergencies, what medicine changes have been made and which team owns follow-up. Rehabilitation needs should be identified alongside disease-specific treatment because mobility, speech and cognition frequently determine outcome.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.